Eli Lilly Surges On Strong Earnings As Mounjaro And Zepbound Sales Soar

📆 08/08/2024 09:33:00
📰 Forbes

⏱ Reading Time:
9 sec. here
11 min. at publisher
📊 Quality Score:
News: 38%
Publisher: 53%

Eli Lilly Notícia

Novo Nordisk,Tirzepatide,Zepbound

Robert Hart is a senior reporter for Forbes covering science, technology and health with a frequent focus on artificial intelligence, space, weight loss drugs and emerging technologies. He joined Forbes in 2020 and is based in London. Rob has covered everything from the billionaire space race, the health impacts of overturning Roe v.

Pharma titan Eli Lilly on Thursday reported strong demand for its weight loss and diabetes drugs Zepbound and Mounjaro, smashing analysts’ expectations in the face ofEli Lilly reported $11.3 billion in revenue and $2.97 billion in net profit for the second quarter of 2024.

Lilly reported $3.28 earnings per share, besting expectations of $2.74, and raised the range of its annual forecast $2.05 to earnings per share between $15.10 to $15.60.

Escrever Comentário

Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação:

Brasil Últimas Notícias, Brasil Manchetes

Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.

Eli Lilly Surges On Strong Earnings As Mounjaro And Zepbound Sales SoarRobert Hart is a senior reporter for Forbes covering science, technology and health with a frequent focus on artificial intelligence, space, weight loss drugs and emerging technologies. He joined Forbes in 2020 and is based in London. Rob has covered everything from the billionaire space race, the health impacts of overturning Roe v.
Fonte: ForbesTech - 🏆 318. / 59 Consulte Mais informação »